Inclusion Criteria:

Histological evidence of progressive or metastatic bone or soft tissue sarcoma.

The following tumor types are included:

- malignant fibrous histiocytoma

- liposarcoma

- synovial sarcoma

- malignant paraganglioma

- fibrosarcoma

- leiomyosarcoma

- angiosarcoma including haemangiopericytoma

- malignant peripheral nerve sheath tumor

- STS, not otherwise specified

- miscellaneous sarcoma including mixed mesodermal tumors of the uterus

- osteosarcoma

- Ewing's sarcoma

- rhabdomyosarcoma

- gastrointestinal stromal tumor (only after failure or intolerance of imatinib or
sunitinib in 1st and 2nd line)

- alveolar soft part sarcoma (ASPS)

- Objective progression of disease may be documented by RECIST criteria. Any of
the following would be sufficient according to RECIST:

- a 20% increase in the sum of unidimensionally measured target lesions

- a new lesion

- unequivocal increase in non-measurable disease.

- Patients must have disease not amenable to surgery, radiation, or combined
modality therapy with curative intent.

- ECOG performance status 0 - 2.

Exclusion Criteria:

Anticancer therapy within 3 weeks of enrollment including chemotherapy, hormonal therapy,
immunotherapy, or radiotherapy.

- The following tumor types will not be included:

- gastrointestinal stromal tumor (except for patients after treatment with
imatinib or sunitinib in 1st and 2nd line)

- chondrosarcoma

- malignant mesothelioma

- neuroblastoma.

- Prior therapy with RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus).

- Neurotoxicity > grade 2 CTC.

- Radiation of the lung.

Other protocol-defined inclusion/exclusion criteria may apply